Hyaluronidase-oysk 2000 UNT/ML / trastuzumab-oysk 120 mg/ML [Herceptin Hylecta]
RxNorm 2375546

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2375546 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: hyaluronidase-oysk 2000 UNT/ML / trastuzumab-oysk 120 mg/ML [Herceptin Hylecta].

The following semantic concepts and normalized strings are associated with this clinical entity:

SBDC
Hyaluronidase-oysk 2000 UNT/ML / trastuzumab-oysk 120 mg/ML [Herceptin Hylecta]
AUI:12408616
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SBDCPrescribable

Semantic Branded Drug Component (SBDC):
Hyaluronidase-oysk 2000 UNT/ML / trastuzumab-oysk 120 mg/ML [Herceptin Hylecta]
(Atom ID: 12408616)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
hyaluronidase-oysk 2000 UNT/ML / trastuzumab-oysk 120 MG/ML [Herceptin Hylecta]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2375546
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12408616
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SBDC
Semantic Branded Drug Component (Ingredient + Strength + Brand Name)
Source Code
2375546
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Patient Education

Trastuzumab and Hyaluronidase-oysk Injection


Trastuzumab and hyaluronidase-oysk injection is used along with other medications or after other medications have already been used to treat a certain type of breast cancer that has spread to other parts of the body. Trastuzumab and hyaluronidase-oysk injection is also used during and after treatment with other medications to decrease the chance that a certain type of breast cancer will return. Trastuzumab and hyaluronidase-oysk injection is in a class of medications called monoclonal antibodies. It works by stopping the growth of cancer cells.
[Learn More]


* Please review the disclaimer below.